Role of interleukin‐6 and endothelin‐1 receptors in enhanced melanocyte dendricity of facial spots and suppression of their ligands by niacinamide and tranexamic acid.

Background: Hyperpigmented spots are common issues in all ethnicities with a hallmark characteristic of increased melanocyte dendricity. Objectives: To determine (1) potential receptors and/or cytokines that are involved in increased melanocyte dendricity in multiple facial spot types; (2) treatment effects of skin‐lightening compounds on identified cytokine release from keratinocytes and on dendricity in melanocytes. Methods: Facial spots (melasma, solar lentigo, acne‐induced post‐inflammatory hyperpigmentation) and adjacent non‐spot skin biopsies were collected from Chinese women (age 20–70). The epidermal supra and basal layers were laser dissected to enrich keratinocyte or melanocyte biology respectively for transcriptome analysis. Melanocyte dendricity was assessed histologically by immunofluorescent staining. Effect of interleukin‐6 (IL‐6) and endothelin‐1 (ET‐1) on melanocyte dendricity and melanosome transfer were assessed in human melanocytes or melanocyte‐keratinocyte co‐culture models. Treatment effects of skin‐lightening compounds (niacinamide, tranexamic acid [TxA], sucrose laurate/dilaurate mixture [SDL]) were assessed on IL‐6 or ET‐1 release from keratinocytes and on dendricity in melanocytes. Results: Transcriptome analysis revealed IL‐6 receptor and ET‐1 receptor were significantly upregulated compared to the adjacent normal skin, visually confirmed at the protein level through immunostaining. Melanocytes in spot areas are more dendritic than melanocytes in adjacent non‐spot skin. The addition of IL‐6 and ET‐1 to cell culture models increased melanocyte dendricity and melanosome transfer. IL‐6 release was significantly suppressed by niacinamide and its combination, while ET‐1 release was significantly reduced by both niacinamide and TxA. In contrast, SDL acted directly upon melanocytes to reduce dendricity. Conclusion: Interleukin‐6 and ET‐1 receptors are significantly upregulated in multiple facial spot types. The in vitro testing demonstrated their respective ligands increased melanocyte dendricity. Tested skin‐lightening compounds showed reduction in release of IL‐6/ET‐1 from epidermal keratinocytes and/or inhibition of melanocyte dendricity. This work sheds light on pathophysiological mechanism of facial spots and potential new mechanisms of these skin‐lightening compounds which warrant further human clinical validation. [ABSTRACT FROM AUTHOR]